Interview with Rogelio Pardo, manager of the Madrid biocluster
Madrid, together with Catalonia, represents more than 80% of the biotechnology industry, but the Community is the location of most of the multinationals. More than 60% of foreign investments are made in Madrid and the capital's research center is the third most important in Europe.
Included in the Madridonbusiness report. Rest of interviews in Madridonbusiness
El Madrid biotechnology cluster It is made up of 40 entities from the five scientific-technological parks of the Community of Madrid. Among its objectives is to work on the international area.
"Nobody creates a biotechnology company to work in their own country; the market is the world, and we try to connect Madrid-based companies with other complementary or synergistic companies to accelerate their processes of bringing research results to market." indicated Rogelio Pardo, manager of Madrid biocluster.
With nearly seven years of existence, the Madrid biocluster emerged as part of the development of the Madrid economy. "We are interested in companies participating in both national and international projects to improve their business," the executive emphasized. They have participated in seven European projects as a full member, with an average budget of between 2 and 3 million euros and between 5 and 7 participating countries.
Currently, this sector is mired in a significant revenue injustice. "Biotechnology companies, due to their size and activity, discover new things or transform traditional sectors of industry. If the revenue generated by biotechnology companies were added to the total revenue generated by these companies, it would be an enormous sector on a global scale," explained Pardo. All the revenue generated by pharmaceutical products brought to market using biotechnological research criteria, as well as by food, biomaterials, fish farming, and other activities, involves biotechnology, but it is not directly billed to the sector.





